{"id":"W4285684531","doi":"10.14283/jpad.2022.48","title":"The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies: An CTAD Task Force Report","year":2022,"lang":"en","type":"article","venue":"The Journal of Prevention of Alzheimer s Disease","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alzheimer Society of Canada","funders":"Avid Radiopharmaceuticals; National Institutes of Health; Genentech; Grifols; H. Lundbeck A/S; National Institute of Neurological Disorders and Stroke; National Institute of General Medical Sciences; Novo Nordisk; Eisai; Prothena; Pfizer; Demensförbundet; Regeneron Pharmaceuticals; GHR Foundation; Danone; Biogen; AstraZeneca; Eli Lilly and Company; Amgen; Alzheimer's Drug Discovery Foundation; Sanofi; National Institute on Aging; Alzheimer's Association","keywords":"Clinical trial; Medicine; Dementia; Amyloid (mycology); Disease; Placebo; Task force; Cognitive decline; Oncology; Internal medicine; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.06904081,0.000203106,0.001332771,0.00006210893,0.00025929,0.00001625777,0.001067081,0.00006719132,0.0004078689],"category_scores_gemma":[0.02102122,0.00008608442,0.001094771,0.0002735707,0.0006677056,0.0001062604,0.0001959823,0.0006398162,4.832445e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001631025,"about_ca_system_score_gemma":0.0004711811,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000002616513,"about_ca_topic_score_gemma":0.000002455291,"domain_scores_codex":[0.9755715,0.01764792,0.004880278,0.0001958768,0.001493219,0.0002112719],"domain_scores_gemma":[0.9486644,0.0387984,0.01034566,0.001264364,0.0007036423,0.0002235706],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","study_design_scores_codex":[0.1192506,0.02939508,0.006552753,0.001270499,0.05894018,0.000440747,0.009313361,0.002023219,0.01009431,0.1492145,0.04304711,0.5704576],"study_design_scores_gemma":[0.005768456,0.005038259,0.02206046,0.0003957091,0.01705234,0.0001385579,0.006869945,0.0001564104,0.001708271,0.936721,0.003789579,0.0003009686],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8786507,0.03326296,0.06443905,0.01439424,0.003754255,0.004588468,0.0006651382,0.00003477354,0.0002104053],"genre_scores_gemma":[0.9711372,0.001175978,0.02671756,0.0001282054,0.0006166052,0.00003030641,0.000002624088,0.00004572622,0.0001458237],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7875065,"threshold_uncertainty_score":0.9872251,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3964248221574626,"score_gpt":0.559941673221779,"score_spread":0.1635168510643164,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}